CYP3A4 and cancer: Similarly, Schwartz et al. found that 800 IU/day vitamin D2 inhibited CYP3A4, raising atorvastatin levels by 17% (p = 0.04) in non-cancer patients [56], suggesting bidirectional pharmacokinetic shifts that could elevate HNC drug levels (e.g., cisplatin) or reduce efficacy.